Moderate Renal Impairment and Risk of Bleeding With Anticoagulation
- 10 December 2012
- journal article
- comment
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 172 (22), 1718-1720
- https://doi.org/10.1001/2013.jamainternmed.456
Abstract
Opinion from JAMA Internal Medicine — Moderate Renal Impairment and Risk of Bleeding With Anticoagulation — Comment on “Enoxaparin Outcomes in Patients With Moderate Renal Impairment”Keywords
This publication has 5 references indexed in Scilit:
- Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin InhibitorClinical and Applied Thrombosis/hemostasis, 2009
- Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly SubjectsClinical Pharmacokinetics, 2008
- Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)American Heart Journal, 2006
- Dosage of enoxaparin among obese and renal impairment patientsThrombosis Research, 2005
- Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndromeClinical Pharmacology & Therapeutics, 2005